Shionogi: Clinical Trials

162 trials sponsored by Shionogi, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

136 completed, 8 recruiting, 8 terminated, 4 not yet recruiting. 66 Phase 1, 48 Phase 3, 42 Phase 2, 5 Phase 4, 2 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 166Completed 57, Recruiting 4, Not yet recruiting 3, Terminated 1, Unknown 1
Phase 348Completed 43, Terminated 3, Recruiting 2
Phase 242Completed 27, Recruiting 5, Terminated 4, Active not recruiting 2, Not yet recruiting 2, Unknown 2
Phase 45Completed 5
Not applicable2Completed 2

Follow Shionogi: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)
S-606001, ERT - Pompe Disease
Phase 2Not yet recruitingShionogi602027-03-312026-11-18
A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD)
S-606001 - Pompe Disease
Phase 1Not yet recruitingShionogi152026-11-302026-11-17
Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls
Sulthiame - Renal Impairment
Phase 1Not yet recruitingShionogi302026-09-292026-10-05
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
Secutrelvir, Placebo - SARS-CoV-2
Phase 3RecruitingShionogi20002026-09-142026-11-17
Study of Secutrelvir in Participants With COVID-19
Secutrelvir, Placebo - COVID-19
Phase 3RecruitingShionogi12002026-08-052026-09-02
A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer
S-531011, Fruquintinib, Pembrolizumab - Metastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer
Phase 1 / Phase 2Not yet recruitingNational Cancer Center Hospital East682026-05-012026-05-18
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
S-337395, Placebo - Respiratory Syncytial Virus Infections
Phase 2RecruitingShionogi1922025-12-112026-10-21
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
S-606001, Placebo - Pompe Disease
Phase 2RecruitingShionogi452025-10-302026-06-23
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
S-892216-PO - Renal Impairment
Phase 1CompletedShionogi242025-10-162026-10-22
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
BPN14770 - Hepatic Impairment
Phase 1CompletedShionogi322025-08-302026-02-27
Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls
BPN14770 - Renal Impairment
Phase 1CompletedShionogi142025-08-252026-02-27
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
S-892216-LAI, Placebo - Healthy Participants
Phase 1RecruitingShionogi1282025-07-292026-10-16
A Study to Assess the Effects of BPN14770 on Rosuvastatin
Rosuvastatin, BPN14770 - Healthy Participants
Phase 1CompletedShionogi122025-07-182025-08-14
Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study
Naldemedine, Placebo - Opioid-Induced Nausea and Vomitting(OINV)
Phase 4CompletedInternational University of Health and Welfare1202025-06-202026-06-03
A Study of S-892216 in Participants With COVID-19
S-892216, Placebo - COVID-19
Phase 2CompletedShionogi2822025-06-062026-09-21
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
BPN14770, Placebo - Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder
Phase 2Active not recruitingShionogi302025-05-132026-06-09
Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
Sivopixant, Placebo, Acetazolamide - Sleep Apnea
Phase 2Active not recruitingShionogi602025-04-022026-05-06
A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants
Ensitrelvir - Healthy Adult Female Participants
Phase 1CompletedShionogi242024-12-302025-05-04
A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants
S-892216, Carbamazepine - COVID-19
Phase 1CompletedShionogi162024-12-172025-03-11
A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants
RSV Infections
CompletedShionogi1002024-12-092025-05-04

Showing 20 of 162. Sign in to see all of them.

Conditions studied

Infections (25)  ·  Acquired Immunodeficiency Syndrome (23)  ·  HIV Infections (11)  ·  COVID-19 (7)  ·  Obesity (7)  ·  Amyotrophic Lateral Sclerosis (6)  ·  Atrophy (6)  ·  Opioid-Induced Constipation (6)  ·  Vaginal Diseases (6)  ·  Renal Insufficiency (5)  ·  Ischemic Stroke (4)  ·  Sepsis (4)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Esophageal Neoplasms (3)  ·  Glycogen Storage Disease (3)

Interventions

dolutegravir (31)  ·  Edaravone (24)  ·  Cefiderocol (11)  ·  Duloxetine Hydrochloride (11)  ·  naldemedine (8)  ·  Ospemifene (7)  ·  ensitrelvir (5)  ·  BPN14770 (4)  ·  Midazolam (4)  ·  Rosuvastatin Calcium (4)  ·  Standard of Care (3)  ·  Tablets (3)  ·  abacavir (3)  ·  baloxavir (3)  ·  cabotegravir (3)

Countries

United States (96)  ·  Japan (50)  ·  Spain (16)  ·  Germany (14)  ·  United Kingdom (14)  ·  Canada (13)  ·  France (13)  ·  Italy (13)  ·  Belgium (9)  ·  Australia (8)  ·  Taiwan (7)  ·  Czechia (6)  ·  Hungary (6)  ·  Poland (6)  ·  South Africa (6)

Top investigators

Hiroshi Shiku, M.D., Ph.D. (2)  ·  Shinichi Kageyama, M.D., Ph.D. (2)  ·  Yataro Daigo, MD, PhD (2)  ·  David Paterson, Professor (1)

Results publications

PMID 32086791, PMID 32280263, PMID 34295186, PMID 34792787, PMID 35585696, PMID 36376130, PMID 39230271, PMID 28576452, PMID 31145214, PMID 32800532, PMID 33393598, PMID 33704925, PMID 33965574, PMID 34377150, PMID 35076335, PMID 37619252, PMID 37953075, PMID 17404091, PMID 19321945, PMID 22298950, PMID 22831708, PMID 23361170, PMID 23817375, PMID 23979733, PMID 24074642, PMID 24096683, PMID 24135530, PMID 24195548, PMID 24446523, PMID 24798770, PMID 24838177, PMID 24944232, PMID 25286015, PMID 25321146, PMID 26262777, PMID 26296539, PMID 26816607, PMID 28371937, PMID 28522181, PMID 28872913, PMID 28872914, PMID 28872915, PMID 28872918, PMID 28872920, PMID 28919811, PMID 29030478, PMID 29713194, PMID 30126675, PMID 30184455, PMID 30271191

NIH funding

2019 (4), 2016 (2), 2018 (2), 2009 (1), 2014 (1), 2015 (1), 2023 (1), 2025 (1)